February 2017

Some see a big market for medications for low libido in women. But sales of Addyi have been slow. Has a normal experience been unnecessarily medicalized?
Jan Greene
Physicians find men lack interest in seeking medical care if they can’t get coverage for erectile dysfunction.
Joseph Burns
A program in New York boosted CD4 counts. It costs more, but people with HIV stay healthier and costs associated with HIV/AIDS could be avoided.
Robert Calandra
Incidence was dipping to all-time lows. Then a perfect storm hit, and the cost is $16 billion a year.
Susan Ladika
Journalist David France’s How to Survive a Plague is a searing firsthand account of the early years of the HIV/AIDS epidemic in New York City. AIDS activists, most of them gay men, were fighting for their lives. Researchers, politicians, public health officials, and pharma were slow to respond—or resisted outright.
Interview by Peter Wehrwein
Jennifer Jones, MD, FRCPC
Mark Borgaonkar, MD, MSc, FRCPC
Jesse Siffledeen, MD, MSc, FRCPC
Ryan O’Reilly, BSc
Dana Anger, MSc



Departments
Legislation & Regulation
Use of long-acting, reversible contraceptives dipped while Medicaid-covered births went up when Texas stopped state funding of Planned Parenthood.
Richard Mark Kirkner
Viewpoint
Why is care for sexual health issues considered a luxury when it’s a necessary part of population health?
Zachary Hafner
Tomorrow's Medicine
Spinraza is a breakthrough, no doubt. But it is another ultraexpensive drug, and the evidence so far points to a modest improvement in motor milestones.
Thomas Morrow, MD